Recombinant Human MDC (67 a.a.) (CCL22)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | MDC is a CC chemokine that is produced in B cells, macrophages, monocyte-derived dendritic cells, activated NK cells and CD4 T cells. It signals through the CCR4 receptor. MDC chemoattracts monocytes, dendritic cells and NK cells and exerts HIV suppressive activity. The 67 amino acid form of MDC displays reduced chemoattractant activity but retains HIV suppressive activity. Recombinant human MDC is an 8.0 kDa protein containing 67 amino acid residues including the four highly conserved cysteine residues present in the CC chemokines. |
---|---|
BiologicalActivity | Determined by its ability to chemoattract human T cells using a concentration range of 10.0-100.0 ng/ml. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human MDC (67 a.a.) (CCL22) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.